QVAR¿ (beclomethasone dipropionate HFA), C4 INHALATION AEROSOL in Aluminum Cylinders, Mktd by: Te...
FDA Drug Recall #D-1190-2014 — Class III — February 11, 2014
Recall Summary
| Recall Number | D-1190-2014 |
| Classification | Class III — Low risk |
| Date Initiated | February 11, 2014 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Teva Pharmaceuticals USA |
| Location | Horsham, PA |
| Product Type | Drugs |
| Quantity | 257,832 cylinders |
Product Description
QVAR¿ (beclomethasone dipropionate HFA), C4 INHALATION AEROSOL in Aluminum Cylinders, Mktd by: Teva Respiratory, LLC, Horsham, PA 19044 Mfd by: 3M Drug Delivery Systems, Northridge, CA 91324.
Reason for Recall
Failed Impurity/Degradation Specification; for 17-BMP at the 9 and 18 month stability time point
Distribution Pattern
Nationwide
Lot / Code Information
lot 120088, exp.3/2014, NDC 59310-202-40, 40 mcg,8.7g / 120 metered inhalations, lot 120491, exp. 10/2014, NDC 59310-175-41,40 mcg,7.3g / 100 metered inhalations
Other Recalls from Teva Pharmaceuticals USA
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0461-2022 | Class II | Doxylamine Succinate and Pyridoxine Hydrochlori... | Jan 18, 2022 |
| D-0520-2022 | Class II | Tretinoin Capsules, 10 mg, 100 count bottle, Rx... | Jan 10, 2022 |
| D-0522-2022 | Class III | Mimvey (estradiol and norethindrone acetate tab... | Jan 7, 2022 |
| D-0521-2022 | Class III | Mimvey (estradiol and norethindrone acetate tab... | Jan 7, 2022 |
| D-0370-2022 | Class II | MethylPREDNISolone Acetate Injectable Suspensio... | Dec 31, 2021 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.